Astra, Daiichi’s Enhertu Boosts Odds of Early Breast Cancer Cure

AstraZeneca Plc and Daiichi Sankyo Co.’s cancer drug Enhertu bolstered outcomes for patients with early-stage breast cancer, results that could extend the blockbuster’s reach to tens of thousands more people and move it closer to a potential cure.

In two pivotal trials presented over the weekend at the European Society for Medical Oncology meeting in Berlin, Enhertu outperformed Roche Holding AG’s Kadcyla in preventing disease recurrence and showed promise when given before surgery. Daiichi shares rose as much as 3.1% in Tokyo trading Monday, helping the stock recover some of this year’s losses. It had fallen 8.2% year-to-date ...